- LexaGene (LXG) announced that a large veterinary animal health corporation has purchased MiQLab Systems for two of its locations
- Both locations will use the MiQLab Systems for fast evidence-based decision making at the point of care
- The MiQLab System is designed for in-clinic use and requires less than a minute to initiate sample processing
- LexaGene is a molecular diagnostics company
- LexaGene Holdings Inc. (LXG) was up 8.33 per cent, trading at C$0.195 per share as of 1:30 pm ET
LexaGene (LXG) announced that a large veterinary animal health corporation has purchased MiQLab Systems for two of its locations.
Both locations will use the MiQLab Systems for fast, evidence based decision-making at the point of care.
The MiQLab System is designed for in-clinic use and requires less than a minute to initiate sample processing. It returns results on the presence of 10 different pathogens and 33 markers for antimicrobial resistance in just 2 hours.
Dr. Jack Regan, CEO and Founder of LexaGene’s commented on the news.
“A month ago, we announced our first multi-system purchase into one of the three major references laboratories servicing the veterinary industry. Today, we announced our first multi-system purchase into a large veterinary corporation. It owns over 100 specialty and emergency pet hospitals and clinics across the United States. We believe our technology will add sufficient value to their business to justify a more aggressive adoption of the MiQLab System throughout their organization.”
LexaGene is a molecular diagnostics company. It develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense.
LexaGene Holdings Inc. (LXG) was up 8.33 per cent, trading at C$0.195 per share as of 1:30 pm ET.
